Opinion

Video

Combination Therapy in Inflammatory Bowel Disease

Author(s):

Silvio Danese, MD, PhD ,Bruce Sands, MD

Medical experts in inflammatory bowel disease discuss the current evidence on dual advanced therapy for ulcerative colitis and Crohn's disease, highlighting the potential benefits, while also addressing the challenges and complexity of treatment management.

  1. What is the current evidence on Advanced Combination Therapy for UC and CD? What are the benefits and challenges of this approach?
Related Videos
Jennifer Flemming, MD | Credit: AASLD
3 experts are featured in this series.
John Kane, MD | Credit: Northwell Health
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Related Content
Shashank Deshpande I Credit: LinkedIn
January 16th 2025

Iclepertin Fails to Improve Cognition in Schizophrenia Phase 3 Study

Chelsie Derman
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes | Image Credit: HCPLive
January 16th 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Technology

Connor Iapoce
Reynold Panettieri, MD, vice chancellor for Translational Medicine and Science at Rutgers University,
January 16th 2025

Elevated Serum cAMP Findings May Allow Asthma Diagnosis by Blood Test

Victoria Johnson
Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program
January 15th 2025

Skin of Color Savvy: News Update—SOCS Awards, My Best Winter Skin, & TORPEDO Program

Robert Brodell, MD
New Dosing Option for Bimekizumab Now Commercially Available for PsA, Psoriasis, HS
January 16th 2025

New Dosing Option for Bimekizumab Now Commercially Available for PsA, Psoriasis, HS

Tim Smith
FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD | Image Credit: US Food and Drug Administration
January 16th 2025

FDA Approves Axatilimab 9 mg and 22 mg Vial Sizes for Chronic GVHD

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.